pharmaceutical
-
Valeant’s year of hell continues but restructuring is on track
The Quebec-based pharmaceutical giant reported a US$302M loss for Q2, but promises progress in the remainder of 2016
-
GlaxoSmithKline says meds are safe despite finding Legionnaires’ in plant
The plant was closed after routine testing found legionella bacteria in two external cooling towers
-
Winnipeg’s Emergent BioSolutions wins 15-year plasma deal
The deal gives Quebec-based Prometic Life Sciences manufacturing flexibility
-
Teva makes US$40B offer to acquire drugmaker Mylan
Had Teva Pharmaceutical Industries Ltd. succeeded, the combination would dominate the global generic drug market
-
Health Canada inspection raises concerns about Quebec vaccine plant
Inspection of GSK vaccine plant in Ste. Foy, Que., comes after infractions raised by U.S. FDA last month
-
Ontario warns feds it wants compensation for sectors hurt by EU trade pact
Ontario Economic Development Minister Eric Hoskins said his government will support the agreement but is concerned about the impacts on the pharmaceutical, dairy, wine and spirits industries.
-
Valeant Pharmaceuticals buys Medicis for US$2.6 billion
Acquisition bolsters Valeant’s presence in prescription skin care market.
-
Teva completes sale of Montreal plant to Halo
Companies also sign a five-year contract manufacturing agreement.
